Such concrete data about the influence of the NLRP3 inflammasome on the molecular pathogenesis of NASH contributed to the concept of the NLRP3 blockade being a therapeutic target. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.